GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical know-how firm centered on the event, manufacturing and commercialization of long-term, implantable steady glucose monitoring (CGM) programs for individuals with diabetes, as we speak introduced the pricing of an underwritten public providing of 8,000,000 shares of frequent inventory at a value to the general public of $5.00 per share, and in lieu of frequent inventory, to sure buyers, pre-funded warrants to buy 8,000,000 shares of frequent inventory at a purchase order value of $4.999 per pre-funded warrant share, which equals the general public providing value per share of the frequent inventory much less the $0.001 train value per share of every pre-funded warrant. The gross proceeds to Senseonics from the providing, earlier than deducting underwriting reductions and commissions and estimated providing bills, are anticipated to be $80 million. As well as, Senseonics granted the underwriters a 30-day choice to buy as much as an extra 2,400,000 shares of frequent inventory on the public providing value, much less underwriting reductions and commissions. The providing is anticipated to shut on Could 4, 2026, topic to satisfaction of customary closing situations. The pre-funded warrants won’t be listed on any securities alternate.
Senseonics intends to make use of the online proceeds from the general public providing to fund the continued launch of Eversense 365 and continued improvement of pipeline merchandise, in addition to for working capital and basic company functions.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or different jurisdiction by which such supply, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or different jurisdiction.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical know-how firm centered on the event, manufacturing and commercialization of glucose monitoring merchandise designed to rework lives within the international diabetes neighborhood with differentiated, long-term implantable glucose administration know-how. Senseonics’ CGM programs Eversense® 365 and Eversense® E3 embody a small sensor inserted fully beneath the pores and skin that communicates with a sensible transmitter worn over the sensor. The glucose knowledge are mechanically despatched each 5 minutes to a cell app on the consumer’s smartphone.
More Read
Ahead-Trying Statements
This press launch incorporates forward-looking statements inside the which means of The Non-public Securities Litigation Reform Act of 1995, together with with out limitation statements relating to, amongst different issues, Senseonics’ expectations concerning the cut-off date of the providing and the anticipated use of proceeds from the providing. The phrases “expects,” “potential,” “may,” “will,” and related expressions are meant to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Precise outcomes or occasions might differ materially from the plans, intentions and expectations disclosed in these forward-looking statements because of numerous essential components, together with dangers regarding Senseonics’ incapacity, or the shortcoming of underwriters, to fulfill the situations to closing for the providing; uncertainties regarding the present financial surroundings, market and different situations; and different dangers and uncertainties which are described within the Danger Components part of Senseonics’ Annual Report on Type 10-Okay for the 12 months ended December 31, 2025, filed with the SEC on March 2, 2026, and different filings Senseonics makes with the SEC every so often. The occasions and circumstances mentioned in such forward-looking statements might not happen, and Senseonics’ precise outcomes might differ materially and adversely from these anticipated or implied thereby. Any forward-looking statements contained on this press launch communicate solely as of the date hereof, and Senseonics expressly disclaims any obligation to replace any forward-looking statements, whether or not due to new data, future occasions or in any other case.
